

## ALOXI ADDITIONAL DISCOUNT PROGRAM FROM MGI PHARMA, INC.



Effective January 20, 2005, Back-end rebates for Aloxi have been replaced with upfront discounts! All OA Members in good standing have the opportunity to earn valuable discounts on Aloxi.

### Upfront Discount Tier I:

- > **ALL** Oncology Associates members IMMEDIATELY qualify for a **6% discount**.
- > To maintain this discount, your practice must purchase a minimum of **50 vials/Full-time physician/Qtr.**

### Upfront Discount Tier II:

- > For those members who had previously reached the maximum 7% rebate, you IMMEDIATELY qualify for a **12% discount**.
- > To maintain this discount, your practice must purchase a minimum of **125 vials/Full-time physician/Qtr.**

### What happens if my practice falls short of my quarterly minimum vial requirement for either tier (50 or 125 vials)?

- > Discount drops to the appropriate tier (or contract price) beginning **May 1, 2005**.
- > Tier I: minimum **50 vials/Full Time Physician/Qtr.**
- > Tier II: minimum **125 vials/Full Time Physician/Qtr.**

### TAKE ACTION! Secure your Aloxi upfront discount...

Contact Oncology Associates if you have not received an Aloxi Eligibility form. Update, sign and return the Aloxi Eligibility form with the correct # of Full-time physicians. **Note: This form only needs to be filled out if your information or number of physicians needs to be updated.**

Please fax the Aloxi Eligibility form to Oncology Associates at **440-995-1540**. 2004 rebates earned from July 1-December 31 will be paid on March 31, 2005 as a credit with FloridaInfusion. Contact Oncology Associates at **888-732-7352** with questions regarding the MGI PHARMA, INC. agreement for Aloxi.

## NEW SANOFI AVENTIS AGREEMENT FOR TAXOTERE®



The current market share agreement for Taxotere® will be ending March 31, 2005. Beginning April 1, 2005, all eligible OA Members in good standing will receive an **upfront 10% discount** on Taxotere® purchases. This new agreement will not require OA Members to report market share via the website.

Taxotere® is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

Taxotere® is also indicated, in combination with cisplatin, for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received chemotherapy for this condition, and as a single agent for patients with locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy.

Please contact OA at **888-732-7352** for questions regarding this agreement.

PRODUCT	DESCRIPTION	NDC#
Taxotere (docetaxel injection concentrate)	20 mg single-dose vial	00075-8001-20
Taxotere (docetaxel injection concentrate)	80 mg single-dose vial	00075-8001-80

## WYETH CONTRACT REMINDER FOR NEUMEGA®



Oncology Associates would like to remind you of its contract for Neumega®. The agreement provides valuable savings for the product Neumega® in 5mg vials and 5mg vials in 7/box quantities.

Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are high risk of severe thrombocytopenia.

Please contact your local Wyeth representative or call OA at **888-732-7352** for more information about the agreement for Neumega®.

NDC#	VIAL SIZE	VIALS/BOX
58394-004-01	5 mg	1 vial; 1x10
58394-004-02	5 mg	1x7